Zhu Mingya, Liu Yongqin, Wen Zhu, Tan Hao, Li Siman, Yu Xinkang, Luo Hongping, Li Delin, Wang Jinyan, Qin Fangyan
Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, People's Republic of China.
The Second People's Hospital of Jiangjin Chongqing, Chongqing, People's Republic of China.
Breast Cancer (Dove Med Press). 2025 Apr 10;17:289-304. doi: 10.2147/BCTT.S511059. eCollection 2025.
Triple-negative breast cancer (TNBC) is recognized as the most aggressive subtype of breast cancer and is associated with poor prognosis. Clinically, TNBC is associated with significant invasiveness, high propensity for metastasis, frequent recurrence, and unfavorable outcomes. The absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2) in TNBC renders it unresponsive to endocrine therapies and treatments that target HER2. Consequently, the current therapeutic options are primarily confined to surgical intervention, adjuvant chemotherapy, and radiotherapy. Given the considerable heterogeneity of TNBC, targeted therapies have emerged as promising avenues for treatment. Furthermore, immunotherapy has demonstrated the potential to enhance overall survival and therapeutic response in patients with TNBC. Additionally, research indicates that traditional Chinese medicine (TCM) may yield beneficial effects in the management of this cancer subtype. This review aims to consolidate recent advancements in treatment strategies for TNBC, particularly those based on molecular subtypes.
三阴性乳腺癌（TNBC）被认为是乳腺癌中最具侵袭性的亚型，且预后较差。在临床上，TNBC具有显著的侵袭性、高转移倾向、频繁复发以及不良预后。TNBC中雌激素受体、孕激素受体和人表皮生长因子受体2（HER2）的缺失使其对内分泌治疗和针对HER2的治疗无反应。因此，目前的治疗选择主要局限于手术干预、辅助化疗和放疗。鉴于TNBC具有相当大的异质性，靶向治疗已成为有前景的治疗途径。此外，免疫疗法已显示出提高TNBC患者总生存期和治疗反应的潜力。另外，研究表明，中药（TCM）可能对这种癌症亚型的治疗产生有益效果。本综述旨在整合TNBC治疗策略的最新进展，特别是基于分子亚型的进展。
